Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie om meer te weten te komen over hoe veilig Darolutamide is en hoe goed het werkt onder reële omstandigheden wanneer het wordt ingenomen in aanvulling op de standaard androgeendeprivatietherapie (ADT) bij Indiase deelnemers met hoogrisico niet-gemetastaseerde castratieresistente prostaatkanker (nmCRPC)

3 november 2026 bijgewerkt door: Bayer

Een eenarmige, open-label fase 4-studie van darolutamide als aanvulling op standaard androgeendeprivatietherapie voor deelnemers in India met hoogrisico niet-gemetastaseerde castratieresistente prostaatkanker (nmCRPC)

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors.

In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant).

Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development.

Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body.

The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate.

Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition to ADT are already available, but this study had no Indian patients and was not conducted in India.

Therefore, the main purpose of this study is to learn how safe darolutamide is when taken in addition to ADT in Indian participants with high-risk nmCRPC.

To answer this question, the researchers will collect all medical problems the participants have that arise during the study and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE). The following information regarding safety of darolutamide will be collected during the study:

  • the number and severity of AEs that are non-serious or serious
  • the number of participants who have to permanently stop the treatment due to AEs
  • the number of participants who have to change the amount of study drug taken due to AEs

AEs can be:

  • abnormal results of laboratory tests, physical examinations, or heart health examinations using ECG (detects heart problems by measuring the electrical activity generated by the heart as it contracts).
  • relevant changes in vital signs
  • relevant changes of the participant's daily living abilities (ECOG performance status)

These results will then be compared with the results from the previous study to identify any differences for this group of participants.

In addition, researchers will collect and compare data on how well darolutamide worked under real world conditions in this group of participants.

All participants will take darolutamide as tablets by mouth twice a day. The participants will visit the study center at the start of the study, and then every 16 weeks until their cancer gets worse, they develop medical problems, they leave the study or until the study is terminated.

During the study, the study team will

  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • examine heart health using ECG
  • assess the participant's ECOG performance status
  • ask the participants questions about how they are feeling and what AEs they are having.

If the trial is stopped, participants may have the option to continue to receive darolutamide, provided they benefit from the treatment

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

50

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Gujarat
      • Nadiād, Gujarat, Indië, 387001
        • Werving
        • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
    • Karnataka
      • Bengaluru, Karnataka, Indië, 560027
        • Werving
        • HCG Oncology Center
    • Kerala
      • Kochi, Kerala, Indië, 682041
        • Werving
        • Amrita Institute of Medical Sciences
      • Thiruvananthapuram, Kerala, Indië, 695011
        • Werving
        • Regional Cancer Centre - Thiruvananthapuram
      • Vellalasseri, Kerala, Indië, 673601
        • Werving
        • MVR Cancer Centre and Research Institute
    • Maharashtra
      • Amravati, Maharashtra, Indië, 444605
        • Actief, niet wervend
        • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation
      • Mumbai, Maharashtra, Indië, 400012
        • Werving
        • Tata Memorial Hospital
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indië, 110001
        • Voltooid
        • Dr. RML Hospital & PGIMER
      • New Delhi, National Capital Territory of Delhi, Indië, 110085
        • Werving
        • Rajiv Gandhi Cancer Institute & Research Centre
    • Odisha
      • Bhubaneswar, Odisha, Indië, 751019
        • Werving
        • All India Institute of Medical Sciences
    • Puducherry
      • Gorimedu, Puducherry, Indië, 605006
        • Nog niet aan het werven
        • Jawaharlal Institute Of Postgraduate Medical Education and R
    • Rajasthan
      • Jaipur, Rajasthan, Indië, 302017
        • Werving
        • Bhagwan Mahaveer Cancer Hospital & Research Centre
    • Telangana
      • Hyderabad, Telangana, Indië, 500096
        • Nog niet aan het werven
        • Apollo Research Foundation
    • Uttar Pradesh
      • Varanasi, Uttar Pradesh, Indië, 221005
        • Werving
        • Mahamana Pandit Madan Mohan Malviya Cancer Centre
    • West Bengal
      • Kolkata, West Bengal, Indië, 700094
        • Werving
        • Netaji Subhas Chandra Bose Cancer Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Beschrijving

Inclusion Criteria:

  • Capable of giving signed informed consent.

  • Participant must be male aged ≥ 18 years.

  • Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.

  • Castration resistance, demonstrated by:

    • a minimum of 3 rising PSA values while the participant is on continuous ADT (started at least 4 weeks prior to the PSA measurement or, PSA measured at least 4 weeks after bilateral orchiectomy) and
    • the interval between each PSA measurement must be ≥ 1 week, and
    • the PSA value at screening must be ≥ 1.0 ng/mL (1.0 μg/L). To confirm this eligibility criterion, it is acceptable for 2 out of the 3 PSA measurements to be taken during the 28-day screening period (after participant has signed consent), provided the measurements are ≥ 1 week apart. In this case, the last PSA value should be recorded as the screening value.
  • Castrate level of serum testosterone (< 1.7 nmol/L [50 ng/dL]) on gonadotropin releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy. Participants who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.

  • PSA doubling time (PSADT) of ≤ 10 months.

  • Eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1.

  • Estimated glomerular filtration rate (eGFR) > 15 mL/min/1.73 m^2.

  • Blood counts at screening: hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥ 1500/μL (1.5 × 109/L), platelet count ≥ 100,000/μL (100 ×109/L) (participant must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).

  • Screening values of serum alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN), total bilirubin (TBL) ≤ 1.5 × ULN (except participants with a diagnosis of Gilbert's disease), creatinine ≤ 2.0 × ULN.

  • Sexually active participants, unless surgically sterile, must agree to use a male condom plus partner use of a contraceptive method with a failure rate of <1% per year, and refrain from sperm donation during the study treatment and for 1 week after the last dose of study treatment. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

  • History of metastatic disease at any time or presence of detectable metastases by investigator assessment within 42 days prior to start of study treatment based on standard medical imaging, i.e., computed tomography/ magnetic resonance imaging (CT/MRI) and bone scan. (Lesions seen on prostate-specific membrane antigen /positron emission tomography (PSMA/PET) scan that are not detected on standard imaging do not exclude participation.) Presence of pelvic lymph nodes < 1.5 cm in short axis below the aortic bifurcation is allowed.

  • Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer.

  • Acute toxicities of prior treatments and procedures not resolved to common terminology criteria for adverse events (CTCAE) v.5.0 grade ≤ 1 or baseline before first dose of study treatment.

  • Severe or uncontrolled concurrent disease, infection, or co-morbidity that, in the opinion of the investigator, would make the participant inappropriate for enrollment.

  • Known hypersensitivity to the study treatment or any of its ingredients.

  • Major surgery within 28 days before first dose of study treatment.

  • Any of the following within 6 months before first dose of study treatment: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association Class III or IV.

  • Uncontrolled hypertension as indicated by a systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg at screening despite medical management. Participants with hypertension can enroll provided BP is stable and controlled by anti-hypertensive treatment.

  • End-stage renal disease (eGFR < 15 mL/min/1.73 m^2).

  • Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥ 5 years ago and from which the participant has been disease-free.

  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.

  • Unstable active viral hepatitis with a need for treatment.

  • Known human immunodeficiency virus (HIV) infection with any of the following (Note: HIV testing is not required unless mandated by local authority):

    • CD4+ T-cell (CD4+) count of less than 350 cells/μL
    • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months
    • On established antiretroviral therapy for less than 4 weeks
    • Presenting with a viral load of more than 400 copies/mL prior to enrollment
    • On antiretroviral therapy or prophylactic antimicrobials that are expected to cause significant drug-drug interactions or overlapping toxicities with study treatment and cannot be changed to alternative agents.
  • Any condition that, in the opinion of the investigator, would impair the participants' ability to comply with the study procedures or study treatment (e.g., unable to swallow study treatment).

  • Unwilling or unable to comply with all protocol-required visits and assessments or comply with study requirements.

  • Prior treatment with:

    • Second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, darolutamide, proxalutamide, etc)
    • Other investigational AR inhibitors
    • Cytochrome P450 (CYP17) enzyme inhibitors (such as oral ketoconazole, abiraterone acetate, TAK-700, etc).
  • Use of first-generation AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before first dose of study treatment.

  • Use of estrogens or 5-α reductase inhibitors (finasteride, dutasteride) within 28 days before first dose of study treatment.

  • Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment completed > 2 years before first dose of study treatment.

  • Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before first dose of study treatment.

  • Radiation therapy (external beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 12 weeks before first dose of study treatment.

  • Treatment with an osteoclast-targeted therapy (bisphosphonate or denosumab) to prevent skeletal-related events within 4 weeks before first dose of study treatment. Participants receiving osteoclast-targeted therapy to prevent bone loss at a dose and schedule indicated for osteoporosis may continue treatment at the same dose and schedule.

  • Treatment with any investigational drug within 28 days before first dose of study treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Darolutamide (BAY1841788)

Participants with high-risk nmCRPC will receive darolutamide.

600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Aantal deelnemers met stopzetting van de studiebehandeling vanwege AE's
Tijdsspanne: Ongeveer 15 maanden
Ongeveer 15 maanden
Aantal deelnemers met dosisaanpassingen van studiebehandeling als gevolg van bijwerkingen
Tijdsspanne: Ongeveer 15 maanden
Ongeveer 15 maanden
Aantal deelnemers met klinisch significante afwijkingen in laboratoriumparameters
Tijdsspanne: Ongeveer 15 maanden
Ongeveer 15 maanden
Aantal deelnemers met klinisch significante elektrocardiogramafwijkingen
Tijdsspanne: Ongeveer 15 maanden
Ongeveer 15 maanden
Aantal deelnemers met klinisch significante afwijkingen bij lichamelijk onderzoek
Tijdsspanne: Ongeveer 15 maanden
Ongeveer 15 maanden
Aantal deelnemers met klinisch significante veranderingen in vitale functies
Tijdsspanne: Vanaf baseline tot ongeveer 15 maanden
Vanaf baseline tot ongeveer 15 maanden
Aantal deelnemers met veranderingen in de prestatiestatus van de oostelijke coöperatieve oncologiegroep (ECOG).
Tijdsspanne: Vanaf baseline tot ongeveer 15 maanden
Vanaf baseline tot ongeveer 15 maanden
Aantal deelnemers met bijwerkingen (AES) en ernstige bijwerkingen (SAE's) en hun ernst.
Tijdsspanne: Ongeveer 15 maanden.
Ongeveer 15 maanden.

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Prostaatspecifiek antigeen (PSA) procentuele verandering vanaf baseline tot 16 weken
Tijdsspanne: Van baseline tot 16 weken
Van baseline tot 16 weken
PSA maximale procentuele daling ten opzichte van baseline op enig moment tijdens de studiebehandeling
Tijdsspanne: Vanaf baseline tot ongeveer 15 maanden
Vanaf baseline tot ongeveer 15 maanden
Tijd tot aanvang van de eerste daaropvolgende systemische antineoplastische therapie
Tijdsspanne: Met ongeveer 15 maanden
Met ongeveer 15 maanden
Tijd tot aanvang van de eerste cytotoxische chemotherapie voor prostaatkanker
Tijdsspanne: Met ongeveer 15 maanden
Met ongeveer 15 maanden

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 augustus 2022

Primaire voltooiing (Geschat)

30 december 2027

Studie voltooiing (Geschat)

30 december 2027

Studieregistratiedata

Eerst ingediend

21 april 2022

Eerst ingediend dat voldeed aan de QC-criteria

21 april 2022

Eerst geplaatst (Werkelijk)

27 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

14 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren